On the 12th, the CDE website announced that Sanofi’s "dual target" antibody dupilumab new drug listing application is planned to be included in the priority review.
On the 12th, CDE website announced that Sanofi's "double target" antibody dupilumab new drug listing application is to be included in the priority review.
On December 12, the CDE website announced that Sanofi's "double target" antibody dupilumab new drug marketing application is planned to be included in the priority review,.<br>